Vaccine Elicitation of HIV Broadly Neutralizing Antibodies from Engineered B cells

Deli Huang, et al.

Like 0 Comment

Received Date: 11th March 20

 >span class="nlm-surname">HuangJenny Tuyet TranAlex Olson >span class="nlm-surname">VollbrechtMariia V. GurylevaMary TenutaRoberta P. FullerTorben SchiffnerJustin R. AbadejosLauren CouvretteTanya R. BlaneKaren SayeWenjuan LiElise LandaisAlicia Gonzalez-MartinWilliam SchiefBen MurrellDennis R. BurtonDavid NemazeeJames E. Voss

HIV broadly neutralizing antibodies (bnAbs) can suppress viremia and protect against infection. However, their elicitation is made difficult by low frequencies of appropriate precursor B cell receptors and the complex maturation pathways required to generate bnAbs from these precursors. Antibody genes can be engineered into B cells for expression as both a functional receptor on cell surfaces and as secreted antibody. Here, we show that HIV bnAb-engineered primary mouse B cells can be adoptively transferred and vaccinated in immunocompetent wild-type animals resulting in the expansion of durable bnAb memory and long-lived plasma cells. Somatic hypermutation after immunization indicated that engineered cells have the capacity to respond to an evolving pathogen. These results encourage further exploration of engineered B cell vaccines as a strategy for durable elicitation of HIV bnAbs to protect against infection and as a contributor to a functional cure.

Read in full at bioRxiv

This is an abstract of a preprint hosted on an independent third party site. It has not been peer reviewed but is currently under consideration at Nature Communications.

Go to the profile of Nature Communications

Nature Communications

Nature Research, Springer Nature